4D Molecular Therapeutics Résultats passés
Passé contrôle des critères 0/6
4D Molecular Therapeutics's earnings have been declining at an average annual rate of -22.1%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 6% per year.
Informations clés
-22.1%
Taux de croissance des bénéfices
29.3%
Taux de croissance du BPA
| Biotechs Croissance de l'industrie | 17.0% |
| Taux de croissance des recettes | 6.0% |
| Rendement des fonds propres | -18.7% |
| Marge nette | -543.5% |
| Dernière mise à jour des bénéfices | 30 Jun 2024 |
Mises à jour récentes des performances passées
Recent updates
4D Molecular Therapeutics: Market Expects Wet AMD Gene Therapy Failure - I'm Not So Sure
Oct 044D Molecular Therapeutics (NASDAQ:FDMT) Is In A Good Position To Deliver On Growth Plans
Aug 10
4D Molecular Therapeutics: R100 Vector Pushes Forward To Bring Q4 Of 2024 DME Data
Jul 194D Molecular Therapeutics: Catalysts With Pioneering Gene Therapy With Directed Evolution
Apr 294D Molecular Therapeutics Advances Wet AMD Treatment Paradigm
Feb 064D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024
Jan 254D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Reported And Analysts Have Been Cutting Their Estimates
Nov 12We're Not Very Worried About 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate
Nov 08Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation
May 08We're Keeping An Eye On 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate
Sep 294D Molecular Therapeutics GAAP EPS of -$0.87, revenue of $0.16M
Aug 11Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation
Jun 11Ventilation des recettes et des dépenses
Comment 4D Molecular Therapeutics gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Jun 24 | 20 | -110 | 41 | 0 |
| 31 Mar 24 | 20 | -105 | 39 | 0 |
| 31 Dec 23 | 21 | -101 | 36 | 0 |
| 30 Sep 23 | 22 | -96 | 34 | 0 |
| 30 Jun 23 | 2 | -111 | 33 | 0 |
| 31 Mar 23 | 2 | -110 | 33 | 0 |
| 31 Dec 22 | 3 | -107 | 33 | 0 |
| 30 Sep 22 | 2 | -105 | 32 | 0 |
| 30 Jun 22 | 3 | -102 | 32 | 0 |
| 31 Mar 22 | 17 | -81 | 31 | 0 |
| 31 Dec 21 | 18 | -71 | 28 | 0 |
| 30 Sep 21 | 17 | -67 | 28 | 0 |
| 30 Jun 21 | 23 | -52 | 23 | 0 |
| 31 Mar 21 | 12 | -60 | 19 | 0 |
| 31 Dec 20 | 14 | -57 | 17 | 0 |
| 30 Sep 20 | 17 | -52 | 16 | 0 |
| 30 Jun 20 | 10 | -61 | 16 | 0 |
| 31 Mar 20 | 8 | -54 | 15 | 0 |
| 31 Dec 19 | 7 | -49 | 14 | 0 |
| 30 Sep 19 | 9 | -35 | 10 | 0 |
| 30 Jun 19 | 13 | -21 | 9 | 0 |
| 31 Mar 19 | 14 | -15 | 8 | 0 |
| 31 Dec 18 | 14 | -10 | 6 | 0 |
| 31 Dec 17 | 6 | -11 | 3 | 0 |
Des revenus de qualité: FDMT is currently unprofitable.
Augmentation de la marge bénéficiaire: FDMT is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: FDMT is unprofitable, and losses have increased over the past 5 years at a rate of 22.1% per year.
Accélération de la croissance: Unable to compare FDMT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: FDMT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Rendement des fonds propres
ROE élevé: FDMT has a negative Return on Equity (-18.68%), as it is currently unprofitable.